|Bid||60.850 x 1000|
|Ask||60.880 x 800|
|Day's Range||59.880 - 61.300|
|52 Week Range||59.880 - 95.930|
|Beta (3Y Monthly)||0.68|
|PE Ratio (TTM)||69.50|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||0.76 (1.21%)|
|1y Target Est||74.67|
NESS ZIONA, Israel, Nov. 13, 2018 -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying,.
Details the CEO buys this past week for the following companies: New Media Investment, American Axle & Manufacturing, Perrigo, IBM and Cooper-Standard Holdings
General Electric Co., Vodafone Group PLC, Ctrip.com International Ltd. and Perrigo Co. PLC have declined to their respective 3-year lows
GW Pharmaceuticals (GWPH) is a developer of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenue of $3.46 million in the third quarter, reflecting a 10.2% year-over-year revenue rise in the quarter.
CEO of Perrigo Co Plc (NYSE:PRGO) Murray S Kessler bought 15,683 shares of PRGO on 11/09/2018 at an average price of $63.79 a share.
NEW YORK, NY / ACCESSWIRE / November 9, 2018 / While shares of healthcare company Perrigo Company were tanking after reporting third quarter financial results, Novelion Therapeutics, which is developing ...
Perrigo lost $12.26, or 16.3%, to $62.88. Perrigo lowered its full-year guidance, as it now sees EPS between $4.45 and $4.65, down from $4.75 to $4.95, on revenue of $4.72 billion, down from $4.8 billion to $4.9 billion. Leerink’s Ami Fada reiterated a Market Perform rating on the stock, writing that “once again the top line continues to be weak and 2018 guidance was lowered primarily due to the prescription segment.” While this “shouldn’t be a complete surprise given prescription trends,” she expected the stock to be weak on the news.
The S&P 500 inched lower on Thursday, as disappointing results from a slew of companies, including Qualcomm Inc, countered gains in bank stocks ahead of the Federal Reserve's interest rate decision. Among the biggest decliners on the benchmark index were Perrigo Co, Wynn Resorts Ltd and D.R. Horton Inc, all falling on disappointing quarterly results.
STOCKSTOWATCHTODAY BLOG One day after the Dow Jones Industrial Average rose more than 500 points, the Dow has advanced 55.40 points, or 0.2%, to 26,235.70, while the S&P 500 has dipped 0.1%, to 55.40, and the Nasdaq Composite has declined 0.
The S&P 500 and the Nasdaq edged lower on Thursday, as weak earnings reports and caution ahead of the Federal Reserve's interest rate decision stalled a rally from the previous session, which was spurred by the outcome for midterm elections. Among the biggest deliners on the S&P 500 were Perrigo Co , Wynn Resorts Ltd and D.R. Horton Inc, all falling on disappointing quarterly results.
Perrigo shares fell sharply after the report and are down nearly 30% so far this year. Perrigo said on the call that problems included an “absence of new products, price erosion in authorized generic products and customer-service challenges resulting in lower sales volumes.” Perrigo plans to sell or spin off the generics business, but it is hard to imagine a buyer will pay a good price to own what is clearly a troubled operation. Perrigo won’t provide financial guidance for 2019 until February, but another decline would mark three consecutive years of falling profits.
The big shareholder groups in Perrigo Company plc (NYSE:PRGO) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a Read More...
Perrigo (PRGO) reports mixed third-quarter 2018 results and lowers revenue and adjusted earnings guidance for 2018 for the second straight quarter.
U.S. stocks edged lower on Thursday, as a clutch of weak earnings reports punctured a rally from the previous session, which was spurred by the outcome for midterm elections. Wynn Resorts Ltd, Perrigo Co and D.R. Horton Inc were the biggest losers on the S&P 500, all falling after reporting disappointing quarterly results. Qualcomm Inc dropped 7.1 percent after the chipmaker forecast sales revenue for the holiday shopping quarter below analysts' estimates, as it took a hit from the loss of chip sales to Apple Inc.
U.S. stock indexes were set to dip on Thursday, following a rally in the previous session that was spurred by relief after the midterm elections, with investor focus shifting to the Federal Reserve's interest rate decision. Stocks gained more than 2 percent on Wednesday after Americans voted for a divided Congress, which was largely anticipated by investors who raised bets that it would be positive for stocks.
Perrigo (PRGO) delivered earnings and revenue surprises of 3.81% and -3.23%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Mergers and acquisitions have been proceeding at a torrid pace, and the health care sector may be an especially active area for future consolidation. In the first half of 2018, the value of M&A deals hit all-time records both worldwide and in the U.S., up by 64% and 79%, respectively, from the first half of 2017, per data from Thomson Reuters cited by Axios.com. Per Business Insider, these are the top 10 takeover candidates that Morgan Stanley sees in the health care sector: IQVIA Holdings Inc. ( IQV), BioMarin Pharmaceutical Inc. ( BMRN), Seattle Genetics Inc. ( SGEN), DaVita Inc. ( DVA), Universal Health Services Inc. ( UHS), Dexcom Inc. ( DXCM), Neurocrine Biosciences Inc. ( NBIX), Perrigo Co. PLC ( PRGO), Nektar Therapeutics ( NKTR), and Sarepta Therapeutics Inc. ( SRPT).
On a per-share basis, the Dublin-based company said it had a loss of 49 cents. Earnings, adjusted for one-time gains and costs, came to $1.09 per share. The results beat Wall Street expectations. The average ...
DUBLIN , Nov. 8, 2018 /PRNewswire/ -- Realized third quarter 2018 GAAP ("reported") net sales of $1.1 billion , reported net loss of $68 million compared to a net income of $45 million last year ...
Perrigo (NYSE: PRGO ) announces its next round of earnings this Thursday, Nov. 8. Here's Benzinga's advanced look at Perrigo's Q3 earnings report. Earnings and Revenue Wall Street analysts see Perrigo ...